Thiophenol-formaldehyde triazole causes apoptosis induction in ovary cancer cells and prevents tumor growth formation in mice model

Group 11 metal complexes of the dinucleating triazole appended bisphosphine 1,4-bis(5-(diisopropylphosphaneyl)-1-phenyl-1H-1,2,3-triazol-4-yl)benzene

The synthesis of a triazole appended dinucleating bisphosphine 1,4-bis(5-(diisopropylphosphaneyl)-1-phenyl-1H-1,2,3-triazol-4-yl)benzene (2) and its coinage metal complexes are described. The dinucleating bisphosphine 2 was obtained by the temperature-controlled lithiation of 1,4-bis(1-phenyl-1H-1,2,3-triazol-4-yl)benzene (1a) and 1,4-bis(1-(2-bromophenyl)-1H-1,2,3-triazol-4-yl)benzene (1b) followed by the reaction with ⁱPr₂PCl. The reactions of 2 with copper(I) halides in 1 : 2 molar ratios yielded the [Cu(μ₂-X)]₂ dimeric complexes [{Cu(μ₂-X)}₂(PⁱPr₂N₃PhC₂)₂C₆H₄] (3, X = Cl; 4, X = Br; and 5, X = I), whereas the reaction of 2 with AgBr resulted in the formation of hetero-cubane complex [{Ag₄(μ₃-Br)₄}{(PⁱPr₂N₃PhC₂)₂C₆H₄}₂] (7). Similar reactions of 2 with AgX in 1 : 2 molar ratios yielded disilver complexes [{Ag(μ₂-X)}₂{(PⁱPr₂N₃PhC₂)₂C₆H₄}] (6, X = Cl and 8, X = I). Treatment of 2 with AgOAc in a 1 : 2 molar ratio afforded a dinuclear complex [Ag₂(μ₂-OAc)₂{(PⁱPr₂N₃PhC₂)₂(C₆H₄)}] (9) with one of the acetate ligands bridging the two metal centres in the side-on mode, whereas the other one adopting the end-on mode keeping the >CO group uncoordinated. The reaction of 2 with two equivalents of [AuCl(SMe₂)] afforded the digold complex [(AuClPⁱPr₂N₃PhC₂)₂C₆H₄] (10). The molecular structures of 2-5 and 7-10 were confirmed by single crystal X-ray analysis. Non-covalent interactions between Cu and C_arene were observed in the molecular structures of 3, 4 and 5. These weak interactions were also assessed by DFT calculations in terms of their non-covalent interaction plots (NCI) and QTAIM analyses.

FAK inhibitors as promising anticancer targets: present and future directions

FAK, a nonreceptor tyrosine kinase, has been recognized as a novel target class for the development of targeted anticancer agents. Overexpression of FAK is a common occurrence in several solid tumors, in which the kinase has been implicated in promoting metastases. Consequently, designing and developing potent FAK inhibitors is becoming an attractive goal, and FAK inhibitors are being recognized as a promising tool in our armamentarium for treating diverse cancers. This review comprehensively summarizes the different classes of synthetically derived compounds that have been reported as potent FAK inhibitors in the last three decades. Finally, the future of FAK-targeting smart drugs that are designed to slow down the emergence of drug resistance is discussed.

Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton

Small molecule inhibitors of the focal adhesion kinase are regarded as promising tools in our armamentarium for treating cancer. Here, we identified four 1,2,4-triazole derivatives that inhibit FAK kinase significantly and evaluated their therapeutic potential. Most tested compounds revealed potent antiproliferative activity in HepG2 and Hep3B liver cancer cells, in which 3c and 3d were the most potent (IC₅₀ range; 2.88 ~ 4.83 µM). Compound 3d possessed significant FAK inhibitory activity with IC₅₀ value of 18.10 nM better than the reference GSK-2256098 (IC₅₀ = 22.14 nM). The preliminary mechanism investigation by Western blot analysis showed that both 3c and 3d repressed FAK phosphorylation comparable to GSK-2256098 in HepG2 cells. As a result of FAK inhibition, 3c and 3d inhibited the pro-survival pathways by decreasing the phosphorylation levels of PI3K, Akt, JNK, and STAT3 proteins. This effect led to apoptosis induction and cell cycle arrest. Taken together, these results indicate that 3d could serve as a potent preclinical candidate for the treatment of cancers.

Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles

The continuous demand of medicinally important scaffolds has prompted the synthetic chemists to identify simple and efficient routes for their synthesis. 1H-1,2,3-triazole, obtained by highly versatile, efficacious and selective "Click Reaction" has become a synthetic/medicinal chemist's favorite not only because of its ability to mimic different functional groups but also due to enhancement in the targeted biological activities. Triazole ring has also been shown to play a critical role in biomolecular mimetics, fragment-based drug design, and bioorthogonal methodologies. In addition, the availability of triazole containing drugs such as fluconazole, furacyclin, etizolam, voriconazole, triozolam etc. in market has underscored the potential of this biologically enriched core in expediting development of new scaffolds. The present review, therefore, is an attempt to highlight the recent synthetic/biological advancements in triazole derivatives that could facilitate the in-depth understanding of its role in the drug discovery process.